| ID: | 89 | |
|---|---|---|
| Name: | Compound 89 | |
| Description: | Original numeration in publication: 3 | |
| Labels: | Training_set, Thiourea | |
| CAS: | ||
| InChi Code: | InChI=1S/C11H11N3O5S2/c12-21(18,19)8-3-1-7(2-4-8)13-9(15)5-14-10(16)6-20-11(14)17/h1-4H,5-6H2,(H,13,15)(H2,12,18,19) |
pIC50: Negative logarithm of half-maximal inhibitory concentration [-log(uM)]
| Value | Source or prediction |
|---|---|
| 6.03 |
Abdelgawad, M. A.; El-Adl, K.; El-Hddad, S. S. A.; Elhady, M. M.; Saleh, N. M. a. K., M. M.; Khedr, F.; Alswah, M. a. N., A. A.; Ghoneim, M. M.; Abd El-Sattar, N. E. A. Design, molecular docking, synthesis, anticancer and anti-hyperglycemic assessments of thiazolidine-2,4-diones bearing sulfonylthiourea moieties as potent VEGFR-2 inhibitors and PPARy agonists. Pharmaceuticals (Basel) 2022, 15, 226. https://doi.org/10.3390/ph15020226 |
| 5.83837 |
Eq1: VEGFR-2 inhibition (Data used to train model) |